Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:e3.
   Google Scholar
• Berneis K, Rizzo M, Lazzaroni V, et al. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92:186–189.
   PubMed Web of Science ®Google Scholar
• González F, Rote NS, Minium J, et al. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab Clin Exp. 2009;58:954–962.
   PubMed Web of Science ®Google Scholar
• Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001;103:1410–1415.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;2:CD007506.
   Google Scholar
• Nybacka Å, Carlstrom K, Stahle A, et al. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertil Steril. 2011;96:1508–1513.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother. 2002;3:1177–1189.
   PubMedGoogle Scholar
• Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol. 2012;3:27–47.
   PubMedGoogle Scholar
• Palomba S, Falbo A, Zullo F, et al. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30:1–50.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340:1314–1320.
   PubMed Web of Science ®Google Scholar
• Unfer V, Facchinetti F, Orrù B, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocarp Connect. 2017;6:647–658.
   PubMed Web of Science ®Google Scholar
• Muscogiuri G, Palomba S, Laganà SA, et al. Inositols in the treatment of insulin-mediated diseases. Int J Endocrinol. 2016;2016:3058393.
   PubMed Web of Science ®Google Scholar
• Thomas MP, Mills SJ, Potter BV. The "Other" inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl. 2016;55:1614–1650.
   PubMed Web of Science ®Google Scholar
• Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443:651–657.
   PubMed Web of Science ®Google Scholar
• Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13:105–110.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitagliano A, Noventa M, et al. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;298:675-684.
   Web of Science ®Google Scholar
• Vitale SG, Rossetti P, Corrado F, et al. How to achieve high-quality oocytes? The key role of myo-inositol and melatonin. Int J Endocrinol. 2016;2016:4987436.
   PubMed Web of Science ®Google Scholar
• Sun TH, Heimark DB, Nguygen T, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002;293:1092–1098.
   PubMed Web of Science ®Google Scholar
• Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care. 1996;19:76–78.
   PubMed Web of Science ®Google Scholar
• Formuso C, Stracquadanio M, Ciotta L. Myo-inositol vs. d-chiroinositol in PCOS treatment. Minerva Ginecol. 2015;67:321–325.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-chiro-inositol. Arch Gynecol Obstet. 2015;291:1181–1186.
   PubMed Web of Science ®Google Scholar
• La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol. 2015;31:52–56.
   PubMed Web of Science ®Google Scholar
• Evans JL, Heymann CJ, Goldfine ID, et al. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled release formulation of alpha-lipoic acid. Endocr Pract. 2002;8:29–35.
   PubMedGoogle Scholar
• Konrad D, Somwar R, Sweeney G, et al. The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both Glut4 translocation and Glut4 activation: potential role of P38 mitogen-activated protein kinase in Glut4 activation. Diabetes. 2001;50:1464–1471.
   PubMed Web of Science ®Google Scholar
• Di Tucci C, Di Feliciantonio M, Vena F, et al. Alpha lipoic acid in obstetrics and gynecology. Gynecol Endocrinol. 2018;34:729–733.
   PubMed Web of Science ®Google Scholar
• De Cicco S, Immediata V, Romualdi D, et al. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecol Endocrinol. 2017;33:698–701.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Shefer K, Della Casa D, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest. 2018;41:583–590.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, authors. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2014;18:1896–1903.
   PubMed Web of Science ®Google Scholar
• Fenkci V, Fenkci S, Yilmazer M, et al. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80:123–127.
   PubMed Web of Science ®Google Scholar
• Moghetti P, Tosi F, Bonin C, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:628–637.
   PubMed Web of Science ®Google Scholar
• Cianci A, Panella M, Fichera M, et al. d-Chiro-inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol Endocrinol. 2015;31:483–486.
   PubMed Web of Science ®Google Scholar
• Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2011;24:161–165.
   PubMed Web of Science ®Google Scholar
• Chiofalo B, Laganà AS, Palmara V, et al. Fasting as possible complementary approach for polycystic ovary syndrome: hope or hype? Med Hypoth. 2017;105:1–3.
   PubMed Web of Science ®Google Scholar